Cystic fibrosis (CF) is one of the most common genetic diseases in the Caucasian population and is characterized by chronic obstructive pulmonary disease, exocrine pancreatic insufficiency, and elevation of sodium and chloride concentrations in the sweat and infertility in men. The disease is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which encodes a protein that functions as chloride channel at the apical membrane of different epithelia. Owing to the high genotypic and phenotypic disease heterogeneity, effects and consequences of the majority of the CFTR mutations have not yet been studied. Recently, the frameshift mutation 3905insT was identified as the second most frequent mutation in the Swiss population and found to be associated with a severe phenotype. The frameshift mutation produces a premature termination codon (PTC) in exon 20, and transcripts bearing this PTC are potential targets for degradation through nonsense-mediated mRNA decay (NMD) and/or for exon skipping through nonsense-associated alternative splicing (NAS). Using RT-PCR analysis in lymphocytes and different tissue types from patients carrying the mutation, we showed that the PTC introduced by the mutation does neither elicit a degradation of the mRNA through NMD nor an alternative splicing through NAS. Moreover, immunocytochemical analysis in nasal epithelial cells revealed a significantly reduced amount of CFTR at the apical membrane providing a possible molecular explanation for the more severe phenotype observed in F508del/3905insT compound heterozygotes compared with F508del homozygotes. However, further experiments are needed to elucidate the fate of the 3905insT CFTR in the cell after its biosynthesis.
INTRODUCTION
Cystic fibrosis (CF; MIM# 219700) is one of the most common autosomal recessive disorders and occurs at a rate of 1 in 1600-3000 Caucasians. The classical symptoms include chronic obstructive pulmonary disease, exocrine pancreatic insufficiency, and elevation of sodium and chloride concentrations in the sweat. 1, 2 Moreover, most males with CF present with infertility as a result of congenital bilateral absence of the vas deferens. 3, 4 CF is caused by mutations in the CF transmembrane conductance regulator (CFTR; MIM# 602421) gene. 5, 6 It encodes a protein that functions as a cAMP-activated chloride channel at the apical membrane of epithelial cells. 7 So far, over 1600 mutations and polymorphisms have been described in the CFTR gene (Cystic Fibrosis Genetic Analysis Consortium; www.genet. sickkids.on.ca/cftr). The genotype-phenotype relation in CF is known to be very complex. Some phenotypic features are closely determined by the genotype in an essentially monogenic manner, whereas others are strongly influenced by both modifying genetic factors and the environment leading to the realization that a disease phenotype is the sum of variable clinical components that arise from different molecular mechanisms of underlying mutations as well as from influences and interplay of many other factors. Thus, this variability in disease manifestation and severity can even be observed among patients carrying the same genotype. In a former study, mutation analysis has revealed that the frameshift mutation 3905insT (c.3773_3774insT) in exon 20 accounts for the second most common (4.8%) CFTR mutation in the Swiss population. 8 The mutation has also been identified to be a common CFTR mutation in the Amish (16.7%) and Acadian (14.3%) population in Pennsylvania and Louisiana, respectively, which are known to have a Swiss descent (Cystic Fibrosis Genetic Analysis Consortium; www.genet.sickkids.on.ca/cftr). Earlier studies based on clinical parameters have shown that the 3905insT mutation is associated with a severe phenotype. [9] [10] [11] [12] The insertion of an additional thymidine in exon 20 leads to a premature termination codon (PTC) in the same exon. It is well known that PTCs can activate the nonsense-mediated mRNA decay (NMD). This control mechanism detects and degrades mRNAs bearing PTCs, thereby preventing the generation of truncated proteins that may be harmful for the cell. 13, 14 During the NMD process, both splicing and translation have a crucial function for the distinction between normal stop codons and PTCs. Until recently, NMD was thought to be triggered when the PTC is located 450-55 nucleotides upstream of the last exon-exon junction (EEJ). 15, 16 However, there is growing evidence that it is rather the physical distance between the PTC and the poly(A) tail, which determines whether a PTC-containing mRNA is an NMD substrate or not. 17, 18 Another mechanism that has recently been associated with PTCs is nonsense-associated alternative splicing (NAS). In contrast to NMD, NAS activates alternative splicing that leads to the removal of the faulty PTC. 14, 19 In this work, we have applied RT-PCR and semi-quantitative analysis to investigate the possible molecular consequences of the frameshift mutation 3905insT at transcript level by analyzing the involvement of NMD and NAS. In addition, we have also performed immunocytochemistry to determine the subcellular localization of the presumably truncated CFTR protein in nasal epithelial cells from patients carrying the mutation.
MATERIALS AND METHODS

Mutation nomenclature
Nucleotide (cDNA) numbering is based on the CF mutation database (http:// www.genet.sickkids.on.ca/cftr) using +1 as the first nucleotide of the reference sequence (GenBank NM_000492.2). Mutation nomenclature according to international recommendations (www.hgvs.org/mutnomen) using +1 as the A of the ATG start codon in the reference sequence is indicated in brackets.
Patients
A total of 16 CF patients seen at the Department of Pediatrics, Inselspital, Berne, Switzerland were selected for this study. Ten patients carried the F508del (p.Phe508del) mutation on one allele and the 3905insT (c.3773_3774insT) mutation on the other. Two patients carried the 3905insT (c.3773_3774insT) mutation on one allele and the P5L (p.Pro5Leu) or the Q39X (p.Gln39X) mutation, respectively, on the other allele. One patient was homozygous for the 3905insT (c.3773_3774insT) mutation and three patients were homozygous for the F508del (p.Phe508del) mutation. All patients fulfilled the consensus for classic CF. 1,2 Informed consent was obtained from all subjects and the local ethics committee approved the study.
Genomic analysis
An EDTA blood sample for DNA analysis was obtained from patients and controls. Mutation screening of the entire coding sequence of the CFTR gene (including the 27 exons, exon-intron boundaries, parts of introns 11 and 19, the promoter region, and the polymorphic sequence 1342-34(TG)10-13(T)3-9 (c.1210-34(TG)10-13(T)3-9) in intron 8) was performed using single-strand conformation polymorphism/heteroduplex analysis with a detection rate of 97.5%. 20 DNA samples presenting with aberrant band patterns on either single or double strands were directly sequenced in both directions.
Cell culture and tissue collection
Human lymphoblastoid cells were prepared by Epstein-Barr virus immortalization of patients' blood lymphocytes. Tissue from the colon and the skin were collected under sterile environment during a surgical intervention. After collection, the tissue was immediately snap frozen and subsequently stored at À801C.
RNA isolation
For EBV-transformed lymphocytes, total cellular RNA was isolated with the Aurum Total RNA Mini Kit (Bio-Rad, Reinach, Switzerland) according to the protocol for cultured cells. The samples were homogenized by passing the lysate 10 times through a 20-G needle fitted to a syringe. DNase treatment was performed according to the protocol. For skin and colon tissue, total RNA was isolated by first grinding frozen tissue in a mortar with liquid nitrogen and then following the protocol for animal tissue of the Aurum Total Mini Kit. The samples were homogenized by passing the lysate 10 times through a 20-G needle fitted to a syringe. DNase treatment was performed according to the protocol. RNA concentration was measured using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Until further processing, the RNA was stored in the presence of 40 Units RNase Inhibitor (Roche, Rotkreuz, Switzerland) at À201C.
RT-PCR
A cDNA fragment encompassing exons 19-24 was amplified in a Perkin Elmer 9700 thermocycler by one-step RT-PCR using the SuperTranscript one-step RT-PCR kit for long templates (Invitrogen, Basel, Switzerland). Reverse transcription was performed at 551C for 30 min. After polymerase activation at 951C for 2 min, 40 cycles of PCR with denaturation at 951C for 15 s, primer annealing at 551C for 30 s, and extension at 681C for 1 min, a final extension at 681C for 3 min was carried out. The primer pairs used were 5¢-ATA CAC AGA AGG TGG AAA TGC, reverse primer 5¢-GTC CCA TGT CAA CAT TTA TGC TGC T. Product identity was confirmed by sequencing on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Warrington, UK).
Agarose gel electrophoresis
A total of 3 ml of the amplification product was mixed with 7 ml of water and 2 ml of loading buffer. The mixture was loaded onto a 2% agarose gel and electrophoresis was performed at 120 V for 2 h. Visualization of the bands was achieved using ethidium bromide and the UV imaging system UviDoc (Witec AG, Littau, Switzerland).
RNA analysis
A cDNA fragment encompassing exons 9-10 was amplified with the one-step RT-PCR kit (Qiagen, Basel, Switzerland) in a LightCycler system (Roche, Basel, Switzerland) with SYBR-Green I to monitor fluorescence increase. Total RNA from a control subject (wild -type, wt) and from a patient homozygous for the F508del mutation was reverse transcribed at 501C for 30 min. After polymerase activation at 951C for 15 min, 45 cycles of PCR with denaturation at 951C for 0 s, and primer annealing at 581C for 25 s, an extension at 721C for 15 s was carried out using the forward primer 5¢-CAGTTTTCCTGGATTATGCCT (exon 10) and the reverse primer 5¢-CTTGGAGATGTCCTCTTCTAGTTG (junction exons 10 and 11) yielding a cDNA of 120 bp for the wt and 117 bp for the F508del. Fluorescence was measured at the end of the elongation step. All reactions were performed in duplicates, and melting curve analysis and sequencing ensured product identity. To compare amplification efficiency, wt and F508del cDNA was purified using the QIAquick purification kit (Qiagen). Subsequently, 10 6 , 10 5 , 10 4 , 10 3 , and 10 2 copies/ml cDNA standards were prepared by serial dilution. The LightCycler Software 3.5 (Roche) automatically generated a standard curve for each cDNA after performing amplification on the LightCycler with 2 ml of each standard under the same conditions mentioned before.
mRNA obtained from F508del/3905insT EBV-transformed lymphocytes was used to perform real-time RT-PCR under the same conditions as described before in this section using the same primer sequences, but with the forward primer being labeled with the fluorescence dye HEX. All reactions were performed in triplicates and RT-PCR was stopped in the exponential phase by monitoring SYBR-Green I fluorescence. A total of 0.5 ml of the amplification product were then subjected to capillary electrophoresis on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The GeneScan-500 ROX Size Standard (Applied Biosystems) was used as an internal standard to determine the size of the amplified fragments. Quantification was performed using the GeneMapper 3.5 software (Applied Biosystems) by comparing the fluorescence peak area of the 3905insT (120 bp) cDNA relative to the one corresponding to the F508del (117 bp) cDNA.
Immunocytochemistry
Lab-Tek II Multichamber slides (Nalge Nunc International, Naperville, IL, USA) were treated with 300 ml of freshly prepared 0.01% (w/v) poly-L-lysine (Sigma-Aldrich, Buchs, Switzerland) solution at 371C for 30 min. The slides were then washed twice with water for 5 min, dried, and eventually stored at 41C until further use. Epithelial cells were collected by nasal brushing. Interdental brushes with 2.5-3 mm bristles (ParoIsola, Thalwil, Switzerland) were used to scrape the inferior turbinates of both nostrils, using two brushes for each side. Cellular material was removed from the brushes by passing the brush through a 100-ml pipette tip with a sectionated tip. The cell suspension was then centrifuged at 5000 rpm for 5 min and the supernatant was removed leaving some liquid over the pellet. Fixation was performed with ice-cold 4% (v/v) formaldehyde/3.7% (w/v) sucrose solution in PBS for 30 min at 41C. The cell suspension was then centrifuged at 3000 rpm for 5 min and the formaldehyde/sucrose solution was completely removed. The cells were resuspended in cold PBS and transferred to the wells of the multichamber slide. After centrifugation at 200 g for 5 min, the liquid was removed from the wells and the samples were air dried for at least 10 min. Permeabilization was performed with PBS+0.1% Triton X-100 for 10 min at RT. The cells were washed twice with PBS and then blocked with PBS+2% normal goat serum (NGS)
(Sigma-Aldrich)+1% BSA (Sigma-Aldrich) for at least 1 h at RT. After five washes with PBS of 5 min each at RT, the cells were incubated over night (16 h) at 41C with one of the two primary antibodies MAB3480 (clone M3A7 against C-terminus) and MAB3484 (clone L12B4 against R region) (Chemicon, Hofheim, Germany) diluted 1:100 in PBS+2% NGS+1% BSA. The cells were then washed five times with PBS for 5 min and incubated for 1 h at RT with an Alexa 488 fluor-conjugated secondary antibody (Molecular Probes goat antimouse) (Invitrogen) diluted 1:200 in PBS+2% NGS+1% BSA. Staining of the Golgi was performed with Alexa 594 fluor-conjugated wheat germ agglutinin from Molecular Probes (Invitrogen). After five washes of 5 min each with PBS at RT, cell nuclei were stained using DAPI from Molecular Probes (Invitrogen). Finally, cells were mounted with ProLong AntiFade Kit from Molecular Probes (Invitrogen). The stained cells were examined using a Nikon Eclipse E600 microscope and a Nikon Digital camera DXM1200.
RESULTS
The PTC introduced by the frameshift mutation 3905insT is insensitive to NMD and NAS Four patients (P1-P4) carrying the 3905insT (c. 3773_3774insT) mutation on one allele and the F508del (p.Phe508del) mutation on the other allele were selected to produce EBV-transformed lymphoblastoid cell cultures. Primers were designed to amplify a region containing the codon for F508del, yielding either a 120-bp fragment for the 3905insT allele or a 117-bp fragment for the F508del allele ( Figure 1a) . As even slight differences in amplification efficiency between the two fragments can considerably influence quantification results, standard curves were created by the LightCycler software for both cDNAs. The obtained curves gave very similar slopes for both cDNAs, indicating that the two fragments were amplified with nearly the same efficiency (Figure 1b) . Extracted RNA from cell cultures was then used to perform real-time RT-PCR on the LightCycler using HEX-labeled primers. Amplification was stopped in the exponential phase of the reaction and the amplification products were subsequently separated by capillary electrophoresis on an ABI3100 genetic analyzer. The GeneMapper software 3.5 was then used to integrate the area under the peaks corresponding to the 3905insT (120 bp) and the F508del cDNA (117 bp). As the F508del mutation is not expected to be affected by NMD, 3905insT transcript levels can be quantified relative to F508del levels. With the exception of P4 (26%), we obtained relative 3905insT mRNA proportions around 50% with values ranging between 45% (P3) and 54% (P1), indicating that the 3905insT allele produces nearly equal transcript levels compared with the F508del allele in P1, P2, and P3 (Figure 1c) . These results strongly suggest that the PTC introduced by the frameshift mutation 3905insT does not cause instability of the corresponding mRNA through NMD.
To verify whether the 3905insT mutation is capable of triggering, an NAS response by inducing skipping of the PTC-containing exon, a region of 817 bp encompassing exons 19-24 was amplified by RT-PCR. Skipping of exon 20 would be expected to result in a 156-bp shorter fragment of 661 bp. However, neither the RNA from EBV lymphocytes (Figure 2a compound heterozygotes and from three F508del homozygous patients. Two different CFTR antibodies were used, which recognize the R region and the C-terminus of CFTR, respectively. Both antibodies were able to detect CFTR at the apical membrane (Figure 3a ) in around 55% of the analyzed nasal epithelial cells derived from controls (Table 1) . Although MAB3484 (R region) distinctively stained the apical region in most cells, MAB3480 (C-terminal) usually also showed a more diffuse labeling, including the subapical region (arrowheads, Figure 3a) . Similarly, in cells from F508del homozygotes, both antibodies were able to detect CFTR at the apical membrane, however, in a reduced number of cells (Table 1) and with weaker apical signals as in wt cells (Figure 3b, arrowheads) . Moreover, in some cells, a CFTR-unspecific intracellular structure was detected, which co-localized with the Golgi compartment (Figure 3b, arrows) . This unspecific staining has earlier been reported in another study in which these two antibodies were also used to detect CFTR in nasal epithelial cells. 21 In contrast to wt and F508del homozygous cells, we observed a significantly reduced amount of nasal epithelial cells from F508del/3905insT compound heterozygotes with an apical staining as compared with F508del homozygotes (Figure 3c ; Table 1 , Pp0.05 ). Again, some cells showed the unspecific Golgi-like intracellular structure (Figure 3c, arrows) . Unfortunately, the only 3905insT homozygous patient in our study was a newborn, and we thus had no possibility to perform a nasal brushing to confirm these findings in 3905insT homozygous cells.
DISCUSSION
The frameshift mutation 3905insT (c. 3773_3774insT) is one of the most common CFTR mutations in the Swiss population 8 and has been associated with a severe phenotype. [9] [10] [11] [12] The mutation is characterized by the introduction of a PTC in exon 20 of the CFTR gene. PTCs can be recognized by the so-called NMD, which degrades transcripts bearing such PTCs thereby preventing the formation of a truncated protein. 14 It has also been proposed that PTCs can be targeted by another mechanism termed NAS, in which the exon containing the PTC is excluded from the mRNA through alternative splicing reducing the levels of full-length CFTR transcripts. 22 Performing a combination of real-time RT-PCR and fragment analysis, we could show that the 3905insT mRNA is insensitive to complete degradation by NMD (Figure 1c ). Three out of four patients showed transcript levels of around 50%, whereas P4 presented with levels of 26% raising awareness of additional complex mechanisms such as individual and tissue-specific expression and/or stability of mRNAs. 23 The lack of degradation by NMD was further confirmed by RT-PCR amplification, in which we were able to detect 3905insT cDNA from skin and colon samples of a 3905insT homozygous patient (Figure 2c) . Moreover, we present evidence that 3905insT transcripts are not subject to alternative splicing by NAS in different tissues of 3905insT carriers ( Figure 2 ). To our knowledge, this is the first CFTR frameshift mutation that has extensively been analyzed for the influence of NMD, and additionally of NAS. Furthermore, it is also the first report of a CFTR frameshift mutation that constitutes an exception to the '50-55 boundary rule' , which states that NMD is triggered whenever a PTC is located 450-55 nucleotides upstream of the last EEJ. 15, 16 There is a growing number of mutations that have been reported to be insensitive to NMD 24-29 supporting a novel model in which the physical distance between the PTC and the poly(A) tail is at least as crucial as the distance between the PTC and the last EEJ. 30 This model might explain the resistance of 3905insT mRNA to NMD, particularly when considering the relative proximity of the emerging PTC to the poly(A) tail. Aberrant proteins produced in the endoplasmatic reticulum (ER) are recognized and then destroyed by a process termed as ERassociated protein degradation (ERAD). 31 It is well established that F508del CFTR is degraded because of a misfolding of the protein that results in an almost complete lack of protein at the plasma membrane. In spite of the degradation, some F508del protein can reach the apical membrane and function as a chloride channel. 32 Several studies have shown that the presence of this residual CFTR activity correlates with a milder CF phenotype in F508del homozygotes. [33] [34] [35] The findings that 3905insT mRNA was insensitive to NMD despite harboring a PTC, led us to the assumption that this mRNA would cause the formation of a truncated protein. To assess the fate of this truncated protein in the cell, we performed immunocytochemical analysis in nasal epithelial cells collected from the patients. In contrast to wt and F508del/F508del cells, in which the CFTR protein could be detected at the apical membrane (Figure 3a) , apical CFTR staining was significantly reduced in nasal epithelial cells derived from F508del/3905insT compoundheterozygous patients (Figure 3c ; Table 1 Effect of CFTR 3905insT at mRNA and protein level J Sanz et al number of cells from F508del homozygous patients have apically localized CFTR (Figure 3b) . 21, 36, 37 Recent studies indicated that the CFTR C-terminus is not required for the biosynthesis and plasma membrane targeting of CFTR, but indispensable for maintaining the stability of the protein. 38 Benharouga et al. 39 could also show that an ERAD-similar mechanism involving the proteasome-ubiquitin pathway may be responsible for the faster turnover and the short residence time at the apical membrane of truncated CFTR. This faster recycling rate of truncated proteins may provide an explanation for the reduced amount of 3905insT CFTR at the apical membrane. However, it has to be noted that the above-mentioned studies investigated protein truncations shorter than 98 amino acids. Owing to the expected large truncation of 216 residues in the 3905insT CFTR, we assume that it is very likely that degradation occurs through the conventional ERAD pathway. Another hypothesis for the complete lack of CFTR at the apical membrane would be that there is an interaction between the F508del and the 3905insT protein somehow hindering each other to reach the plasma membrane. In conclusion, the reduced presence of CFTR protein at the apical membrane may provide a possible explanation for the more severe phenotype observed in 3905insT/ 
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Golgi CFTR (C-term) Golgi Figure 3 Immunocytochemical analysis of CFTR in nasal epithelial cells derived from controls (a), from F508del/F508del patients (b), and from F508del/ 3905insT patients (c). CFTR was detected using either an antibody directed against the C-terminal or the R region of the protein, and the Golgi compartment was stained using wheat germ agglutinin. Arrowheads indicate CFTR localized at the apical membrane of the cells, whereas arrows display an unspecific Golgi-like structure earlier mentioned in the literature.
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F508del compound-heterozygous patients versus F508del homozygous patients, in which at least some CFTR can escape the ER, reach the apical membrane, and function as a chloride channel. However, further experiments need to be performed to see whether the truncated 3905insT protein is degraded before reaching the apical membrane, whether it is quickly recycled after reaching the membrane, or whether there is an interaction between the 3905insT and the F508del CFTR protein interfering with the transport to the apical membrane.
